THE NEXT GENERATION IMMUNO-ONCOLOGY COMPANY
To serve the patients who need advancements in therapy to extend quality of life.
The full CD47 story has yet to be told. We have identified the challenges facing the CD47 field and have devised a path forward where the full potential of CD47/SIRPα checkpoint blockade can be realized without side-effects. This path forward requires the technology and expertise of Caprice Therapeutics.